Guess which ASX All Ords stock is up 60% in just two days

This ASX share is smashing the market this week. But why?

| More on:
surprised asx investor appearing incredulous at hearing asx share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price is rising again on Wednesday.

At one stage today, the ASX All Ords share was up 27% to 8.4 cents.

When the clinical stage immuno-oncology company's shares reached that level, it meant they were up just over 60% in the space of two days.

The Imugene share price has eased back a touch since then but remains up 17% to 7.7 cents.

Why is this ASX All Ords stock on fire?

Investors have been buying the company's shares this week following the release of a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial which is evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

According to the release, the company's study has delivered positive early signals.

It notes that 34 heavily pre-treated patients have been dosed to date with the CF33-hNIS virus. All treatments have been determined safe and tolerable.

One Complete Response (CR) was recorded in bile duct cancer in the mid dose on study for over 350 days. Whereas one Partial Response (PR) in melanoma in the mid dose was record. 16 patients had Stable Disease (SD).

Importantly, early results from 6 patients with gastrointestinal cancers who received CF33-hNIS alone including 2 colorectal cancer, 2 bile duct, 1 pancreatic and 1 liver cancer showed positive treatment effects, with a disease control rate (all CR, PR and SD) of 75%.

The ASX All Ord Stock's CEO, Leslie Chong, was pleased with the results. She said:

Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. The early positive response data we are seeing at the mid-dose level in hard-to-treat bile duct cancer suggests that VAXINIA may be a potent anti-cancer drug as we interrogate higher dose levels. With no adverse safety signals, thus allowing us to dose higher, VAXINIA will have a very high therapeutic window which is valuable in oncology drug development.

Despite its heroics this week, the Imugene share price is down almost 60% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Can NIB shares reach $9 by Christmas?

It has been a good few weeks for shareholders. Can the stock keep going?

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Broker Notes

CSL shares up 15% in 5 weeks amid two hedge funds placing opposing bets

Let's see what these funds have to say about CSL shares.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Why is the Mesoblast share price sinking 25% on Tuesday?

This biotech is being sold off today. But why?

Read more »

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »